Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesHematology/OncologyBCBS MA hemophilia therapies Prior Auth | OpenPaye…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - MassachusettsPolicy 360

    Factor and Non-Factor Anti-Hemophilic Therapies (Hemophilia and Related Coagulation Disorders)

    Customize your policy alerts

    Sign up for Blue Cross Blue Shield - Massachusetts Policy 360 alerts

    Get alerted when Policy 360 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Medical-benefit coverage policy for a broad set of coagulation factor and non-factor anti-hemophilic drugs (including factor VIII, IX, X, XIII, fibrinogen concentrate, anti-inhibitor complexes, TFPI antagonists, von Willebrand products, and related agents) for Commercial members (multiple product-specific indications described). Prior authorization is required. Policy does not apply to Medicare Advantage members.

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyFactor and Non-Factor Anti-Hemophilic Therapies (Hemophilia and Related Coagulation Disorders)
    Policy CodePolicy 360
    Change TypeLabeling / coding updates (non-material)
    Effective DateJan 15, 2026
    Last ReviewJan 15, 2026
    Next Review Date
    Key ActionPrior authorization is required for medical-benefit hemophilia and related coagulation factor/non-factor therapies; requests must be submitted to Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department via phone, fax, or mailed Formulary Exception/Prior Authorization form.
    SourceLink
    POLICY UPDATE CHANGES

    Updated Vonvendi's expanded indication.

    Updated FDA labeling for Alhemo and updated formatting and references.

    Updated HCPCS codes for Qfitlia and Alhemo; added Qfitlia previously.

    MultipleProducts/Classes Covered (count approximate)
    Commercial onlyPlan Scope
    Prior AuthorizationUtilization Management Requirement

    Coverage Summary

    This policy covers a broad set of medical-benefit coagulation therapies including coagulation factor concentrates (Factor VIII, IX, X, XIII), von Willebrand factor products, fibrinogen concentrate, anti-inhibitor coagulant complexes, and non-factor agents (e.g., TFPI antagonists, factor IXa-/X-directed antibodies, siRNA agents). Indications include treatment and prevention of bleeding in hemophilia A and B (including with or without inhibitors), von Willebrand disease, congenital factor deficiencies (e.g., Factor X, XIII, fibrinogen), and acquired factor deficiencies. Coverage under this document is for Commercial members only (medical benefit), and prior authorization is required for these medications.

    Quick Policy Facts
    Plan ScopeCommercial only
    Utilization Management RequirementPrior Authorization
    Factor VIII trough threshold>= 1%
    Age thresholds>= 12 years (where applicable)

    Medical-Necessity Criteria

    Policy Summary
    PayerBlue Cross Blue Shield - Massachusetts
    PolicyFactor and Non-Factor Anti-Hemophilic Therapies (Hemophilia and Related Coagulation Disorders)
    Policy CodePolicy 360
    Change TypeLabeling / coding updates (non-material)
    Effective DateJan 15, 2026
    Last ReviewJan 15, 2026
    Next Review Date
    Key ActionPrior authorization is required for medical-benefit hemophilia and related coagulation factor/non-factor therapies; requests must be submitted to Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department via phone, fax, or mailed Formulary Exception/Prior Authorization form.
    SourceLink
    On This Page
    Coverage SummaryMedical-Necessity CriteriaCodingProvider ActionsBackground and EvidenceRevision HistoryDefinitions & Thresholds

    General Coverage Statements

    ANY of the following

    • Anti-Inhibitor Coagulant Complex is indicated for the control of spontaneous bleeding episodes or to cover surgical interventions in hemophilia A and hemophilia B patients.
    • Routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients aged 12 years and older with hemophilia A or B with or without factor VIII or IX inhibitors.
    • Coagulation factor indicated for the treatment of bleeding episodes and perioperative management in adults and children with hemophilia A or B with inhibitors, congenital Factor VII (FVII) deficiency, and Glanzmann's thrombasthenia with refractoriness to platelet transfusions, with or without antibodies to platelets & Treatment of bleeding episodes and perioperative management in adults with acquired hemophilia.
    • Human anti-hemophilic factor (AHF) maintenance therapy (prophylaxis) as needed to maintain trough levels at 1% or greater in patients with severe Hemophilia A (AHF activity less than 1% of normal).>= 1%
    • Human anti-hemophilic factor (AHF) for treatment and/or management of bleeding episodes in surgical patients with mild hemophilia (AHF activity 5%-30%) or moderately severe hemophilia (AHF activity 1%-5%).
    • Human antihemophilic factor (AHF) for treatment of moderate to severe Von Willebrand's disease in appropriate settings, for example, major surgery, trauma.
    • Human anti-hemophilic factor (AHF) for acquired factor VIII deficiency.
    • On-demand treatment and control of bleeding episodes.
    • Coagulation Factor IX concentrate indicated in adults and children with hemophilia B (congenital Factor IX deficiency) control and prevention of bleeding episodes, perioperative management, and routine prophylaxis control and prevention of bleeding episodes.
    • Coagulation Factor IX [Recombinant] is an antihemophilic factor indicated in adults and children with hemophilia B for: Control and prevention of bleeding episodes, perioperative management, on-demand treatment, and routine prophylaxis.
    • Plasma-derived human blood coagulation Factor X indicated in adults and children (aged 12 years and above) with hereditary Factor X deficiency for On-demand treatment and control of bleeding episodes and perioperative management of bleeding in patients with mild or moderate hereditary Factor X deficiency.
    • Routine prophylaxis for bleeding in patients with congenital factor XIII A-subunit deficiency.
    • Factor IXa- and factor X-directed antibodies are indicated for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients with hemophilia A (congenital factor VIII deficiency) with or without factor VIII inhibitors.
    • Fibrinogen Concentrate indicated for the treatment of acute bleeding episodes in patients with congenital fibrinogen deficiency.
    • Tissue factor pathway inhibitor (TFPI) antagonists (Alhemo, Hympavzi) for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric patients 12 years of age and older with hemophilia A or hemophilia B, with or without respective inhibitors, per product-specific labeling.
    • Recombinant Von Willebrand Factor for treatment (on demand) and control of bleeding episodes, perioperative management, and routine prophylaxis in adult and pediatric patients with von Willebrand disease.
    • We do not cover Factor and Non-Factor Anti-Hemophilic Drugs for conditions other than those listed above.

    Prior Authorization and Individual Consideration

    ALL of the following

    • Prior authorization is required for coverage of Factor and Non-Factor Anti-Hemophilic Drugs under this medical benefit policy for Commercial Members (Managed Care HMO/POS, PPO/EPO, Indemnity).
    • To request prior authorization, physicians may call, fax, or mail the Formulary Exception/Prior Authorization form to: Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department, 25 Technology Place, Hingham, MA 02043. Tel: 1-800-366-7778. Fax: 1-800-583-6289.
    • Requests that do not meet the clinical criteria of this policy may be submitted for Individual Consideration. For Individual Consideration, physicians should send relevant clinical information for the individual patient to: Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department, 25 Technology Place, Hingham, MA 02043. Tel: 1-800-366-7778. Fax: 1-800-583-6289. Decisions will be made based on the member's unique clinical circumstances and current scientific literature.

    Coding

    HCPCS codes listed (informational; coverage requires meeting medical necessity criteria)HCPCS
    J7174Injection, fitusiran, 0.04 mg (Qfitlia)
    C9132Factor IX : Prothrombin complex concentrate (human), per i.u. of Factor IX activity (Kcentra)
    J7173Injection, concizumab-mtci (Alhemo)
    C9304Injection, marstacimab-hncq, 0.5 mg (Hympavzi)
    C9399Unclassified drugs or biologicals (NOC) (i.e. Hemlibra)
    J7170Injection, emicizumab-kxwh, 0.5 mg
    J7175Injection, factor x, (human), 1 i.u. (Coagadex)
    J7177Injection, human fibrinogen concentrate (fibryga), 1 mg
    J7178Injection, human fibrinogen concentrate, not otherwise specified, 1 mg (RiaSTAP)
    J7179Injection, Von Willebrand factor (recombinant), 1 i.u. vwf:rco (Vonvendi)
    1–10 of 39
    1/4
    CPT codesCPT
    No codes listed

    Inclusion of a code in this policy is informational and does not guarantee coverage or reimbursement; providers should report services using current CPT/HCPCS/ICD-10 codes and modifiers and verify member-specific benefits. Coverage for listed codes requires that the medical necessity criteria in this policy be met.

    Provider Actions

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required for medical-benefit hemophilia and related coagulation factor and non-factor therapies. Requests must be submitted to Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department.

    • Phone: 1-800-366-7778
    • Fax: 1-800-583-6289
    • Mail: Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department, 25 Technology Place, Hingham, MA 02043 (use Formulary Exception/Prior Authorization form)
    Documentation Required

    Individual Consideration Process

    Clinicians may request individual consideration for patients whose clinical circumstances do not meet the policy's clinical criteria by submitting relevant clinical information for review by the Pharmacy Operations Department.

    • Mail: Blue Cross Blue Shield of Massachusetts Pharmacy Operations Department, 25 Technology Place, Hingham, MA 02043
    • Fax: 1-800-583-6289
    • Phone: 1-800-366-7778
    Billing Rule

    Use industry-standard codes and modifiers

    Report services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes (CPT/HCPCS/ICD-10) including modifiers where applicable. Inclusion of a code in this policy is informational only and does not guarantee coverage or reimbursement; medical necessity criteria must be met for coverage.

    Background and Evidence

    This policy references FDA-approved indications and product package inserts for specific therapies and addresses both prophylaxis (routine maintenance to prevent bleeding) and on-demand treatment (control of acute bleeding or perioperative management). Product-specific labeling and indications are noted where they differ (for example, VonVendi's expanded routine prophylaxis indication was recently updated).

    References: product package inserts (multiple products including Advate, Alhemo, VonVendi, Hemlibra and others) and clinical guidance (e.g., World Federation of Hemophilia guidelines) are cited to support the policy.

    Revision History

    1/15/2026labeling updateLatest

    Updated Vonvendi's expanded indication (policy history notes change dated 1/15/2026 updating Vonvendi labeling and indication).

    11/2025labeling and formatting update

    Updated FDA labeling for Alhemo and updated formatting and references (policy history entry 11/2025).

    2025coding and product updates

    Multiple policy history entries in 2025 reflecting coding updates and added products: updated HCPCS codes for Qfitlia and Alhemo (10/2025), added Qfitlia to the policy (7/2025), and other administrative/coding updates noted across 2025.

    Definitions & Thresholds

    Definitions and Thresholds
    Medical benefit (MED)Indicates coverage under the medical (not pharmacy) benefit; prior authorization managed by Pharmacy Operations Department.
    Factor VIII trough level for prophylaxis>= 1% (maintain trough levels at 1% or greater in severe Hemophilia A)
    Age threshold>= 12 years (where applicable; e.g., Factor X and TFPI antagonist indications)